GSE132194
Global altered gene expression in  triple-negative breast cancer tumor samples treated with CDK2 and EZH2 inhibitors
Triple-negative breast cancer cell line SUM-149 xenograft mouse model was treated with CDK2 inhibitor (dinaciclib) and EZH2 inhibitor (EPZ6438) for 10 days to examine global transcriptome alternations by RNAseq. Expression levels of more than 801 and  741 gene were altered by CDK2 inhibitor and EZH2 inhibitor treatment, respectively.Among differential changed genes induced by CDK2 inhibitor and EZH2 inhibitor, we defined top 109 common up- and down-regulated gene sets in the inhibitor-treated tumors. Overall design: Global gene changes in triple-negative breast cancer xenograft mouse model treated with CDK2 and EZH2 inhibitors was examined by RNAseq